METiS Pharmaceuticals Strengthens Leadership Team with Appointment of Mark Herbert as Chief Business Officer
核心洞察
METiS Pharmaceuticals (搜索) has appointed Mark Herbert, former President of Arcturus Therapeutics (搜索), as Chief Business Officer to lead global business development and strategic partnerships.
The company's AI-driven LNP delivery systems have demonstrated up to 20-fold greater efficacy in liver cancer (搜索) and lung tumors (搜索) compared to industry standards.
Herbert brings over 20 years of biotech industry experience, having previously generated over $2 billion in partnership value through strategic collaborations with companies like Takeda and CureVac.
METiS Pharmaceuticals (搜索), a clinical-stage biotechnology company specializing in AI-driven drug delivery technologies, has appointed Mark Herbert as its Chief Business Officer (CBO), effective January 22, 2025. Herbert will spearhead the company's global business development initiatives and forge strategic partnerships to accelerate the commercialization of its innovative drug delivery platforms.
Strategic Leadership Addition
Herbert joins METiS with over two decades of experience in the biotechnology and pharmaceutical sectors. As the former President of Arcturus Therapeutics (搜索), he orchestrated strategic collaborations with industry giants Takeda Pharmaceutical (搜索) and CureVac, generating partnerships valued at over $2 billion. His extensive portfolio includes executive positions at Varda Space Industries and Scientist.com, along with board memberships across multiple biotech companies.
Dr. Chris Lai, Co-founder and CEO of METiS Pharmaceuticals (搜索), emphasized the strategic importance of the appointment: "Mark's proven track record in driving business development and commercialization in the biotech space will be instrumental in strengthening our partnerships and unlocking new growth opportunities as we enter this crucial phase."
Breakthrough Technologies in Drug Delivery
METiS has achieved significant technological breakthroughs in its AI-driven lipid nanoparticle (搜索) (LNP) delivery systems. The company's innovative platforms have demonstrated remarkable efficacy in targeted nano delivery across multiple organs, including the liver, lungs, spleen, muscles, and central nervous system. Notably, these advanced delivery systems have shown up to 20 times greater efficacy in treating liver cancer (搜索) and lung tumors (搜索) compared to current industry standards.
"METiS is at the forefront of using AI to revolutionize drug delivery," Herbert stated. "I'm excited to work with the team to advance our cutting-edge nucleic acid and drug delivery technologies and expand our global partnerships."
Expanding Global Partnerships
Since its founding in 2020, METiS has established itself as a pioneer in programmable nucleic acid therapeutics and next-generation RNA (搜索) delivery. The company has already secured strategic collaborations with more than 20 leading global pharmaceutical and biotech companies, positioning itself for significant growth in the drug delivery sector.
Dr. Hongmin Chen, Co-founder and CRDO of METiS Pharmaceuticals (搜索), noted: "Mark's deep industry knowledge and global perspective will be invaluable as METiS accelerates its growth. His leadership will help enhance our business development efforts and foster partnerships that will bring our transformative drug delivery technologies to patients around the world."